Entera achieved FDA alignment for EB613 in July 2025 and is pursuing strategic partnership discussions to optimize development and commercialization across its pipeline. The company appointed former Pfizer executive Geno J. Germano as Chairman in February 2026, signaling institutional strengthening ahead of key clinical milestones.
Cyborg Score Rationale
Entera plans Phase 3 protocol submission for EB613 in Q1 2026 following FDA qualification of BMD as a regulatory endpoint, and aims to accelerate EB612 into clinic in 2026. However, the company faces significant clinical execution risks and limited revenue generation as a pre-commercial stage asset.
Top Insights
FDA qualified BMD as a regulatory endpoint for EB613 in December 2025, clearing pathway for Phase 3 osteoporosis trial planned for Q1 2026
Next-Gen EB613 Phase 1 bridging study initiated November 2025 with results expected end Q1 2026; company accelerating long-acting oral PTH (EB612) into clinic in 2026
Entera continues strategic partnership discussions across pipeline to optimize development and commercialization pathways for first-in-class oral peptide programs
Company maintains research collaboration with OPKO Biologics; incorporated 2009
Named Competitors
Semaglutide (Ozempic, Wegovy) — Injected GLP-1 for obesity and diabetes
Gattex — Injected GLP-2 for short bowel syndrome
Teriparatide (Forteo) — Injected PTH(1-34) for osteoporosis
Carbaglu — Oral therapy for hyperammonemia in hypoparathyroidism
Recent Developments
(Feb 2026) Appointed former Pfizer executive Geno J. Germano as Chairman
(Jan 2026) Announced Q1 2026 corporate priorities including EB613 Phase 3 protocol submission and EB612 acceleration
(Dec 2025) FDA qualified BMD as regulatory endpoint for EB613; robust preclinical PK/PD data for long-acting PTH announced
Open the full interactive Entera Bio Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.